TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034.
Tumor necrosis factors are a group of cytokines that are secreted by macrophages and may induce cell death of certain tumor cell lines, which leads to inflammation. TNF inhibitors are the drug that stops inflammation. They are mainly indicated for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, anklyosing Spondilitis They are also called TNF blockers. Currently only five TNF are approved which include humira (adalimumab), remicade (infliximab), cimzia (Certolizumab pegol), enbrel (etanercept), and simponi (golimumab). Humira is the king and bestselling drug of the century due to high clinical efficacy and is approved for multiple indications. Entry of biosimilar in the market, major patent expiry of blockbuster drug, and strong ongoing clinical pipeline of biosimilar has boosted the growth of TNF biosimilar market. Moreover, the rising incidence and prevalence of rheumatic disease and switching trends from traditional treatment to biologic therapy have increased the growth of the market. However, stringent government regulation and entry of other promising therapy in the market hamper the growth of the market.
The global TNF biosimilar market is segmented by drug, distribution channel, and geography. On the basis of drug the global market is further sub segmented into Adalimumab biosimilars (Amjevita, Yusimry, Cyltezo, Exemptia, and others (including products approved in developing countries and pipeline products)), Infliximab biosimilars (Avsola (infliximab-axxq), Flixabi (SB2), Inflectra (infliximab-dyyb), Zessly, and others), Certolizumab biosimilars, Etanercept biosimilars, (Benepali, Nepexto, Eticovo, Erelzi, and others), Golimumab biosimilars. Infliximab biosimilar segment followed by etanercept biosimilar segment is expected to hold significant share of the market due to early patent expiry and entry of biosimilars like erie Etanercept-szzs and Infliximab-dyyb into the major market like Europe and United States. On the basis of distribution channel the global market is segmented into online pharmacy, hospital pharmacy, and retail pharmacy. Hospital pharmacy segment dominates the global market followed by retail pharmacy and online pharmacy. Online pharmacy segment is expected to grow at high CAGR due to the increase in number internet user and ease of use.
At regional level, the global TNF biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, Europe followed by North America is major contributor for the global TNF biosimilar market. This is because strong ongoing clinical pipeline of biosimilars, increasing research and drug development activities, presence of major players, and increase in demand for biosimilars propels the growth of the market in the region. Asia Pacific is the third promising revenue contributor which is expected to grow at a rapid pace in upcoming year. Countries such as Japan, India, and China are major contributors to this market. Emerging and colossal population base countries such as China and India offer tremendous market opportunities for the TNF biosimilar market. Entry of biosimilar will increase patient affordability and accessibility which in turn increase in consumption of TNF in low-income countries.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 16.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug, By Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Alvotech, Amgen, Amgen Inc., AYUMI Pharmaceutica, Biocon, Biogen, Biosimilar Collaborations Ireland Limited, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Cordavis Ltd., Epirus Biopharmaceuticals, Fresenius Kabi, Glenmark Pharmaceuticals, Hanwha Chemical, Hetero, Innovent Biologics, Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics), LG Chem, Lupin, Mabpharm, Merck, Mylan, Nichi-Iko Pharmaceutical, Organon & Co., Pfizer, Ranbaxy Laboratories (now Sun Pharma), Samsung Bioepis, Sandoz, Shanghai CP Guojian Pharmaceutical, Sorrento Therapeutics (partner), Stada Arzneimittel AG, Sunshine Guojian Pharmaceutical, Synermore, Teva, Torrent Pharmaceuticals, YL Biologics, Zydus Cadila, and other prominent players. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global TNF Biosimilars Market Snapshot
Chapter 4. Global TNF Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global TNF Biosimilars Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on TNF Biosimilars Market Industry Trends
Chapter 5. TNF Biosimilars Market Segmentation 1: By Drug, Estimates & Trend Analysis
5.1. Market Share by Drug, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug:
5.2.1. Adalimumab biosimilar
5.2.1.1. Amjevita
5.2.1.2. Yusimry
5.2.1.3. Cyltezo
5.2.1.4. Exemptia
5.2.1.5. Others (Products approved in developing countries & pipeline products)
5.2.2. Infliximab biosimilar
5.2.2.1. Avsola (infliximab-axxq)
5.2.2.2. Flixabi (SB2)
5.2.2.3. Inflectra (infliximab-dyyb)
5.2.2.4. Zessly
5.2.2.5. Others (Products approved in developing countries & pipeline products)
5.2.3. Certolizumab biosimilar
5.2.4. Etanercept biosimilar
5.2.4.1. Benepali
5.2.4.2. Nepexto
5.2.4.3. Eticovo
5.2.4.4. Erelzi
5.2.4.5. Others (Products approved in developing countries & pipeline products)
5.2.5. Golimumab biosimilar
Chapter 6. TNF Biosimilars Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Rheumatoid Arthritis
6.2.2. Psoriasis
6.2.3. Inflammatory Bowel Disease
6.2.4. Ankylosing Spondylitis
6.2.5. Others
Chapter 7. TNF Biosimilars Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
7.2.1. Hospital Pharmacy
7.2.2. Retail Pharmacy
7.2.3. Online Pharmacy
7.2.4. Others
Chapter 8. TNF Biosimilars Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global TNF Biosimilars Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.2.3. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.3. Europe
8.3.1. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.3.3. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.4.3. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.5. Latin America
8.5.1. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.5.3. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.6.3. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Alvotech
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Amgen
9.2.3. Amgen Inc.
9.2.4. AYUMI Pharmaceutica
9.2.5. Biocon
9.2.6. Biogen
9.2.7. Biosimilar Collaborations Ireland Limited
9.2.8. Boeheringer Ingelheim
9.2.9. Celltrion
9.2.10. Cipla
9.2.11. Coherus Biosciences
9.2.12. Cordavis Ltd.
9.2.13. Epirus Biopharmaceuticals
9.2.14. Fresenius Kabi
9.2.15. Glenmark Pharmaceuticals
9.2.16. Hanwha Chemical
9.2.17. Hetero
9.2.18. Innovent Biologics
9.2.19. Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
9.2.20. LG Chem
9.2.21. Lupin
9.2.22. Mabpharm
9.2.23. Merck
9.2.24. Mylan
9.2.25. Nichi-Iko Pharmaceutical
9.2.26. Organon & Co.
9.2.27. Pfizer
9.2.28. Ranbaxy Laboratories (now Sun Pharma)
9.2.29. Samsung Bioepis
9.2.30. Sandoz
9.2.31. Shanghai CP Guojian Pharmaceutical
9.2.32. Sorrento Therapeutics (partner)
9.2.33. Stada Arzneimittel AG
9.2.34. Sunshine Guojian Pharmaceutical
9.2.35. Synermore
9.2.36. Teva
9.2.37. Torrent Pharmaceuticals
9.2.38. YL Biologics
9.2.39. Zydus Cadila
9.2.40. Other prominent players
Global TNF Biosimilars Market Outlook, by Drug
Global TNF Biosimilars Market Outlook, by Application
Global TNF Biosimilars Market Outlook, by Distribution Channel
Global TNF Biosimilars Market Outlook By Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
